• Explore /
  • Poster
  • / Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.

Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.

Abstract Poster

Authors

null

Mark Christopher Markowski

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Mark Christopher Markowski , Christopher Michael Pieczonka , Robert H. Getzenberg , Domingo Rodriguez , K. Gary Barnette , Mitchell S. Steiner , Daniel R. Saltzstein , Emmanuel S. Antonarakis , Ronald F. Tutrone , Mario A. Eisenberger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03752099

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5049)

DOI

10.1200/JCO.2022.40.16_suppl.5049

Abstract #

5049

Poster Bd #

233

Abstract Disclosures

Similar Posters

First Author: Mark Christopher Markowski

First Author: Mark Christopher Markowski

First Author: Mark Christopher Markowski

First Author: Evan Y. Yu